Briacell Therapeutics's Comment on Sales, Marketing and Customers
BriaPro is a pre-clinical stage immunotherapy company focused on developing binding agents and proteins to enhance the activity of cancer-fighting cells. The company utilizes artificial intelligence through its Receptor AI platform to identify drug candidates, including BP-80 (soluble CD80) for cancer immunotherapy, B7H3/Bria-TILsRx™ multi-specific binding reagents for targeted cancer immunotherapy, and protein kinase C delta inhibitors. BriaPro plans to initiate clinical studies for these candidates between 2025 and 2028. Additionally, the company is developing high-affinity antibodies against B7-H3, an immune checkpoint molecule expressed on various tumor types, for incorporation into its Bria-TILsRx™ platform. This platform is designed to activate tumor-infiltrating lymphocytes within the tumor microenvironment by engaging multiple cancer-associated and immune pathway targets to address immune suppression and T cell exhaustion. Customers and markets associated with BriaPro include BriaCell, ImmunoPrecise Antibodies, and Receptor AI.
Navigating New Frontiers in Metastatic Breast Cancer: BriaCell s Pioneering Phase 3 Clinical UpdateIn a transformative moment for oncological therapeutics, BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSX: BCT) has announced a significant clinical engagement update regarding its pivotal Phase 3 study involving Bria-IMT, an innovative immunotherapy designed for patients battling metastatic breast cancer (MBC). This announcement, made on October 15, 2024, marks a critical juncture in the company s ongoing mission to redefine cancer care through advanced immunological strategies.The Phase 3 study aims to enroll up to 354 patients, who will be randomly assigned in a 1:1 ratio to receive either the BriaCell...
Briacell Therapeutics’s Comment on Sales, Marketing and Customers
BriaPro is a pre-clinical stage immunotherapy company focused on developing binding agents and proteins to enhance the activity of cancer-fighting cells. The company utilizes artificial intelligence through its Receptor AI platform to identify drug candidates, including BP-80 (soluble CD80) for cancer immunotherapy, B7H3/Bria-TILsRx™ multi-specific binding reagents for targeted cancer immunotherapy, and protein kinase C delta inhibitors. BriaPro plans to initiate clinical studies for these candidates between 2025 and 2028. Additionally, the company is developing high-affinity antibodies against B7-H3, an immune checkpoint molecule expressed on various tumor types, for incorporation into its Bria-TILsRx™ platform. This platform is designed to activate tumor-infiltrating lymphocytes within the tumor microenvironment by engaging multiple cancer-associated and immune pathway targets to address immune suppression and T cell exhaustion. Customers and markets associated with BriaPro include BriaCell, ImmunoPrecise Antibodies, and Receptor AI.
Sources:
Briacell Therapeutics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Briacell Therapeutics Corp’s corporate clients.
For your research, we’ve provided 9 tables on Briacell Therapeutics Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
